Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.53 |
| ▸ | STAT3 | P40763 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | FLT3 | P36888 | 2/20 | 0.50 |
| ▸ | CDK2 | P24941 | 2/20 | 0.50 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.50 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.47 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.47 |
| ▸ | ITK | Q08881 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 3/20 | 0.47 |
| ▸ | GSK3A | P49840 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2144970 | 0.84 | FLT3 (0.55) | KDM4EYTHDC1STAT3HIF1AFLT3 | |
| SCHEMBL17113551 | 0.83 | KDM4E (0.58) | DYRK1AKDM4EYTHDC1STAT3HIF1A | |
| SCHEMBL1980525 | 0.83 | NTRK1 (0.53) | DYRK1AKDM4EYTHDC1STAT3HIF1A | |
| SCHEMBL628628 | 0.81 | GSK3B (0.70) | DYRK1ACDK2GSK3BGSK3ACDK1 | |
| SCHEMBL4487525 | 0.81 | GSK3B (0.73) | DYRK1ACDK2AAK1GSK3BGSK3A | |
| SCHEMBL627899 | 0.80 | FGFR1 (0.65) | DYRK1AYTHDC1FLT3CDK2CCNA2 | |
| SCHEMBL31040239 | 0.80 | FGFR1 (0.65) | DYRK1AYTHDC1FLT3CDK2CCNA2 | |
| SCHEMBL13524671 | 0.79 | DYRK1A (0.71) | DYRK1AAAK1ITKGSK3B | |
| SCHEMBL622021 | 0.79 | FLT3 (0.59) | YTHDC1FLT3CDK2CCNA2CCNA1 | |
| SCHEMBL19100555 | 0.79 | MAPK1 (0.53) | DYRK1AKDM4EYTHDC1STAT3HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1487804-B1 | AMINOINDAZOLE DERIVATIVES AS PROTEIN-KINASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2014-02-26 | — | — | EP | claimed |
| JP-4648630-B2 | — | — | 2011-03-09 | — | — | JP | claimed |
| JP-2005530711-A | — | — | 2005-10-13 | — | — | JP | claimed |
| US-6949579-B2 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2005-09-27 | — | — | US | claimed |
| EP-1487804-A2 | AMINOINDAZOLE DERIVATIVES AS PROTEIN-KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2004-12-22 | — | — | EP | claimed |
| US-20040014802-A1 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2004-01-22 | — | — | US | claimed |
| WO-2003078403-A2 | DERIVES D’AMINOINDAZOLES COMME INHIBITEURS DE PROTEINE-KINASE | AVENTIS PHARMA S.A. (FR) | 2003-09-25 | — | — | WO | claimed |
| US-20230416205-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | TENVIE THERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
| EP-3399968-B1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS PHARMATECH LTD (KY) | 2021-10-20 | — | — | EP | disclosed |
| US-10435388-B2 | Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase | CS PHARMATECH LIMITED (KY) | 2019-10-08 | — | — | US | disclosed |
| US-20190023689-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | HIGH GREAT INVESTMENT LIMITED (HK) | 2019-01-24 | — | — | US | disclosed |
| EP-3399968-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS Pharmatech Limited (KY) | 2018-11-14 | — | — | EP | disclosed |
| WO-2017120429-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS Pharmasciences, Inc. (US) | 2017-07-13 | — | — | WO | disclosed |
| EP-1487804-A2 | AMINOINDAZOLE DERIVATIVES AS PROTEIN-KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2004-12-22 | — | — | EP | disclosed |
| US-20040254177-A1 | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | NERVIANO MEDICAL SCIENCES S.R.L (IT) | 2004-12-16 | — | — | US | disclosed |
| EP-1432416-A1 | AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Pharmacia Italia S.p.A. (IT) | 2004-06-30 | — | — | EP | disclosed |
| US-20040014802-A1 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2004-01-22 | — | — | US | disclosed |
| WO-2003097610-A1 | AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PHARMACIA ITALIA S.P.A. (IT) | 2003-11-27 | — | — | WO | disclosed |
| WO-2003078403-A2 | DERIVES D’AMINOINDAZOLES COMME INHIBITEURS DE PROTEINE-KINASE | AVENTIS PHARMA S.A. (FR) | 2003-09-25 | — | — | WO | disclosed |
| WO-2003028720-A1 | AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PHARMACIA ITALIA S.P.A. (IT) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014802-A1 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | CYP2C8, NR0B2, NR2C2 | DYRK1A 1638/4885KDM4E 3563/4885YTHDC1 3671/4885 |
| US-10435388-B2 | Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase | EGFR, ERBB3, ERBB2 | DYRK1A 168/4885KDM4E 1867/4885YTHDC1 4592/4885 |
| US-20040254177-A1 | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | MAP3K15, MAP3K3, MAP3K5 | DYRK1A 387/4885KDM4E 1085/4885YTHDC1 4629/4885 |
| US-20230416205-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | NLRP3, NLRP1, NOD1 | DYRK1A 3523/4885KDM4E 3822/4885YTHDC1 1507/4885 |
| US-20190023689-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | EGFR, ERBB3, ERBB2 | DYRK1A 168/4885KDM4E 1867/4885YTHDC1 4592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.